Takeda Pharmaceutical Company Limited (LON:0A87)

Market Cap	33.69B
Revenue (ttm)	23.26B
Net Income (ttm)	1.06B
Shares Out	n/a
EPS (ttm)	0.66
PE Ratio	31.87
Forward PE	n/a
Dividend	0.41 (2.96%)
Ex-Dividend Date	n/a

Volume	1,806
Average Volume	2,192
Open	13.93
Previous Close	14.98
Day's Range	13.93 - 13.93
52-Week Range	10.01 - 11.99
Beta	n/a
RSI	53.80
Earnings Date	May 8, 2025

About LON:0A87

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A...

• Industry: Pharmaceutical Preparations
• Founded: 1781
• Employees: 49,281
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A87

Financial Performance

In 2023, LON:0A87's revenue was 4.26 trillion, an increase of 5.87% compared to the previous year's 4.03 trillion. Earnings were 144.07 billion, a decrease of -54.56%.

Financial numbers in JPY